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aim of this study was to examine the impact of GM2AP on glucose metabolism in vivo. Injection
of recombinant GM2AP in mice signiﬁcantly lowered blood glucose levels in glucose tolerance tests.
Administration of GM2AP to mice for 10 days increased serum insulin levels, whereas the contents
of glucose, leptin and FFA were signiﬁcantly decreased. Stimulation of calcium inﬂux and insulin
secretion by GM2AP was observed in hamster insulinoma HIT-T15 cells. Blockage of GM2AP function
by speciﬁc antibodies inhibited GM2AP-induced insulin secretion. These results provide novel
insights into the physiological functions of GM2AP in obesity.
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Obesity is a well-known risk factor for development of hyperin-
sulinemia, insulin and leptin resistance, type II diabetes, dyslipide-
mia, hypertension, atherosclerosis and Alzheimer’s disease [1–3].
Numerous studies have revealed that adipose tissue is a major
endocrine organ secreting a variety of bioactive substances such
as adiponectin, resistin, angiotensinogen, TNF-a, plasminogen acti-
vator inhibitor-1, visfatin, retinol-binding protein 4, fatty acids, sex
steroids, and a number of growth factors [4–7]. However, the
precise functions of the included adipokines in development of
obesity-related disorders are not fully understood.
GM2AP is a small (20 kDa), stable (heat stable at 60 C), long-
lived, protease-resistant protein that normally resides in the lyso-
zome [8]. First synthesized as a precursor which is then glyocosy-
lated, modiﬁed, and cleaved at 32Ser to become the mature form,
GM2AP contains at least three functional elements: a hydrophobic
pocket called the b-cup structure, an oligosaccharide binding site,
and an area that interacts with b-hexosaminidase A (Hex A) [9].
It acts as a cofactor essential for the degradation of ganglioside
GM2 by Hex A and in addition has been reported to bind to, and
act in transport of, a broad spectrum of lipids including phosphati-chemical Societies. Published by E
r protein; Hex A, b-hexosa-
ctivating factor
aka 3-chome, Konohana-ku,
p (K. Higashi).dylcholine, the most common phospholipid in eukaryotes [10–13].
Interestingly, GM2AP also binds to platelet activating factor (PAF:
1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) within b-cup
and hydrolyzes it to inactive lyso-PAF (1-O-alkyl-sn-glycero-3-
phosphocholine) [14]. Indeed, administration of recombinant
GM2AP inhibited the devastating gastrointestinal necrosis result-
ing from the injection of rats with PAF and LPS [8].
Mutations in the GM2AP gene cause GM2-gangliosidosis AB
variant, in which gangliosides accumulate in neuronal cells. In con-
trast, up-regulation of GM2AP expression by oxidized LDL en-
hances ganglioside accumulation in the aorta, which may be
strongly associated with atherosclerosis [15]. We have recently
demonstrated that GM2AP is a novel adipokine whose expression
is augmented by adipogenesis [16]. In addition, treatment of cul-
tured cells with GM2AP impairs both insulin and NGF signal trans-
ductions [16]. The present study was conducted to examine the
effects of GM2AP on glucose metabolism in mice.2. Materials and methods
2.1. Cell culture, plasmids and reagents
Hamster insulinoma HIT-T15 cells were grown in DMEM sup-
plemented with 10% FCS. Recombinant mouse GM2AP was pre-
pared using a baculovirus expression system (Takara, Japan) as
previously described [16]. Brieﬂy, recombinant protein was pre-
pared from baculovirus-infected High Five cells, and puriﬁed bylsevier B.V. All rights reserved.
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pharose 4B chromatography [17]. The purity of mouse GM2AP
determined by Coomassie Brilliant Blue (CBB) staining was above
99% (Fig. 1A). Two rabbit anti-human GM2AP antibodies were pre-
pared against CDEGKDPAVIRSL (aa 39–51; amino-terminus) or
CPFKEGTYSLPKSEFVV (aa 138–154; b-cup) peptides of human
GM2AP, and cross-reactivity with mouse GM2AP was conﬁrmed
by western blot analysis [16]. A cholinergic agonist carbachol
was purchased from Nacalai Tesque (Osaka, Japan).
2.2. Mice
Experimental procedures described were carried out according
to the guidelines and were approved by the Experimental Animal
Research Committee for Ethics and Animal Experimentation, Nihon
Bioresearch Inc. (Gifu, Japan). For glucose tolerance tests (GTTs), 8-
week-old male C57BL/6J mice (Clea Japan, Osaka, Japan) were in-
jected intraperitoneally (i.p.) with 0.3 or 3 mg/kg of recombinant
mouse GM2AP or vehicle before starting an overnight fast, and
were further dosed 12 h and 16 h later. Two hours after the last
dose, glucose (2 g/kg, i.p.) was injected and blood glucose was
measured at set time points. For 10 day-repeated injections of
GM2AP experiments, blood was taken without prior fasting at days
10 and 15 for performance of serological tests. Glucose, total cho-
lesterol and triglycerides were measured by glucose oxidase, cho-
lesterol oxidase and GPO-DAOS methods, respectively. The
contents of insulin, leptin and angiotensinogen were determined
using commercially available ELISA kits. All other serological tests
were performed by automated colorimetric assay using an Olym-
pus AU400.
2.3. Calcium inﬂux
Changes in intracellular calcium concentration were monitored
using Screen Quest Fluo-8 Medium Removal Calcium Assay Kit
(AAT Bioquest Inc., Sunnyvale, CA). Brieﬂy, hamster insulinoma
HIT-T15 cells were loaded with 1 lM Fluo-8 in CO2 incubator for
30 min, and then incubated with pluronic F127 containing Hanks’
with 20 mM HEPES buffer (pH 7.0) for another 30 min at room
temperature. Fluorimetric data were acquired in a FDSS3000 scan-
ning ﬂuorimeter (Hamamatsu Photonics, Japan). Excitation and
emission ﬁlter were set to 480 and 540 nm, respectively. The90
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Fig. 1. GM2AP lowers serum glucose levels in the intraperitoneal glucose tolerance
test. (A) Recombinant mouse GM2AP was prepared using a baculovirus expression
system. Staining with Coomassie Brilliant Blue shows the presence of a protein
marked with asterisks on the left. (B) Mice were injected intraperitoneally with 0.3
or 3 mg/kg of GM2AP before starting an overnight fast, and were further dosed 12 h
and 16 h later. Two hours after the last dose, glucose (2 g/kg, i.p.) was injected and
serum glucose was measured at set time points. Data shown are mean ± S.D. values.
⁄P < 0.05, N = 10.FDSS3000 was set to run for 15 min, collecting data at 1.09 s
interval.
2.4. Insulin secretion in vitro
HIT-T15 cells were incubated with various doses of recombi-
nant GM2AP for 20 min in Krebs–Ringer containing 1.1 mM glu-
cose and the released insulin was determined using an ELISA kit
(Morinaga Institute Biological Science, Yokohama, Japan).
2.5. Statistical analysis
Values are expressed as mean ± S.D. The non-parametric
Shirley–Williams’ multiple comparison test was used to evaluate
the statistical signiﬁcance of differences between groups.3. Results
3.1. Effects of GM2AP on glucose-loaded serum glucose levels
We have recently demonstrated that treatment of cultured adi-
pocytes or myocytes with GM2AP impairs insulin signaling [16].
We explored the possibility that administration of GM2AP might
inﬂuence glucose metabolism in vivo. Serum GM2AP content in
C57BL/6J mice was 4 lg/ml, estimated about 0.3 mg/kg, and
7.5 lg/ml in obese mice [16]. A preliminary pharmacokinetic study
showed that a single injection of 3 mg/kg of GM2AP led to an
approximate six-fold increase of serum GM2AP 2 h later, with a re-
turn to the basal level 6 h thereafter (data not shown). As shown in
Fig. 1B, administration of 3 mg/kg of GM2AP signiﬁcantly reduced
both basal and glucose-loaded serum glucose levels. In addition, a
dose-dependent diminution of glucose-loaded serum glucose con-
centration was observed, suggesting an impact of GM2AP on glu-
cose metabolism. To ﬁnd the effects of GM2AP on insulin
secretion in vivo, serum insulin levels were determined. Although
single injection of GM2AP had no effects on basal serum glucose or
insulin levels, GM2AP signiﬁcantly reduced glucose-loaded serum
glucose levels in parallel with the increase of serum insulin con-
centration (Supplementary Fig. 1A and B). These results suggested
that GM2AP stimulates insulin secretion in vivo.
3.2. Effects of GM2AP on serological proﬁles
We next performed 10 day-repeated injections of GM2AP
followed by serological tests. On Day 10, blood was collected 8 h
later after last dosing without prior fasting. To assess recovery after
withdrawal of exposure, serological tests were also undertaken on
Day 15 without prior fasting. As shown in Fig. 2A, injection of
3 mg/kg of GM2AP for 10 days signiﬁcantly reduced blood glucose
at both time points, with no signiﬁcant effects on food intake or
body weight (Table 1). In addition, we found that administration
GM2AP augmented serum insulin levels in a dose-dependent man-
ner at Day 10 (Fig. 2B). Interestingly, exposure of 3 mg/kg of
GM2AP to mice signiﬁcantly reduced leptin concentrations at
Day 10 (Fig. 2C). In addition, administration of GM2AP diminished
the serum FFA and increased c-GTP content in a dose-dependent
manner at Day 15 (Table 1). However, serum concentrations of to-
tal cholesterol, triglyceride, AST, ALT, ALP, LDH, CPK, BUN, creati-
nine and angiotensinogen were not changed by GM2AP at Day
15 (Table 1).
3.3. Effects of GM2AP on insulin secretion in vitro
The above ﬁndings raised the possibility that GM2AP stimulates
insulin secretion, resulting in lowered blood glucose levels.
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Fig. 2. GM2AP has effects on glucose and lipid metabolism. (A–C) Mice were
injected intraperitoneally with 0.3 or 3 mg/kg of GM2AP once a day for 10 days.
Serum was collected at days 10 and 15, for performance of serological tests. (A)
Glucose, (B) insulin, (C) leptin. Data shown are mean ± S.D. values. ⁄P < 0.05, N = 10.
Table 1
Serological proﬁles of GM2AP-injected mice at Day 15. Mice were injected intraper-
itoneally with 0.3 or 3 mg/kg of GM2AP once a day for 10 days. Blood was taken at
day 15, for performance of serological tests.
Measurement Vehicle 0.3 mg/kg 3 mg/kg
Body weight gain, g 1.0 ± 0.2 1.2 ± 0.2 1.0 ± 0.2
Food intake, g/day 3.94 ± 0.09 4.03 ± 0.08 4.10 ± 0.09
Total cholesterol, mg/dl 97.6 ± 2.7 97.4 ± 1.5 94.0 ± 1.3
Triglyceride, mg/dl 66.5 ± 5.2 59.4 ± 3.4 58.8 ± 2.4
FFA, lEq/L 502.5 ± 44.5 450.8 ± 28.6 407.9 ± 19.0⁄
AST, IU/L 46.6 ± 3.6 51.1 ± 3.5 53.2 ± 5.1
ALT, IU/L 22.6 ± 1.8 25.6 ± 2.7 25.0 ± 2.4
ALP, IU/L 236.6 ± 9.8 237.8 ± 8.1 245.2 ± 5.9
LDH, IU/L 271.3 ± 30.8 255.0 ± 22.5 272.1 ± 27.2
CPK, IU/L 427.4 ± 168.6 336.7 ± 75.8 306.6 ± 76.5
c-GTP, IU/L 0.00 ± 0.00 0.23 ± 0.04⁄ 0.32 ± 0.12⁄
Total bilirubin, mg/dl 0.10 ± 0.00 0.10 ± 0.00 0.11 ± 0.00
BUN, mg/dl 32.4 ± 0.9 28.0 ± 0.9 31.5 ± 1.8
Creatinine, mg/dl 0.09 ± 0.00 0.08 ± 0.00 0.10 ± 0.01
Angiotensinogen, lg/ml 2.80 ± 0.10 2.85 ± 0.03 2.87 ± 0.11
Data shown are mean ± S.D. values. N = 10.
FFA, free fatty acid; AST, aspartate aminotransferase; ALT, alanine aminotransfer-
ase; LDH, lactate dehydrogenase; CPK, creatine phosphokinase; c-GTP, c-glutamyl
transpeptidase; BUN, blood urea nitrogen.
⁄P < 0.05
K. Higashi et al. / FEBS Letters 585 (2011) 2587–2591 2589Opening of calcium channels and acceleration of calcium inﬂux is
necessary and sufﬁcient to trigger insulin secretion [18]. To exam-
ine effects of GM2AP on insulin secretion, hamster insulinoma HIT-
T15 cells were exposed to GM2AP, and intracellular calcium con-
centration and insulin content in culture medium were deter-
mined. A cholinergic agonist carbachol produced a fast increase
of intracellular calcium concentration, returning to basal level after
1 min (Fig. 3A, open circle). A similar result with carbachol was ob-
tained from 0.1 mM ATP (data not shown). In contrast, treatment
of cells with GM2AP increased intracellular calcium concentration
slowly, and sustaining the increase throughout the experiments
(Fig. 3A, closed circle). In addition, GM2AP resulted in a dose-
dependent elevation of calcium inﬂux at 15 min after exposure
(Fig. 3B). A previous study has suggested that cationic amino acid
arginine depolarize b-cells without direct interaction with an ionic
channel [19]. Treatment of HIT-T15 cells with arginine exhibited
the same pattern of calcium inﬂux as GM2AP, and GM2AP aug-
mented arginine-stimulated intracellular calcium concentration
(Supplementary Fig. 2). Next, the concentration of insulin in cul-ture medium was analyzed using an ELISA. As shown in Fig. 3C,
exposure of cells to GM2AP led to a marked increase in insulin con-
tent in a dose-dependent manner. However, GM2AP had no effects
on cell viability (data not shown). To clarify functional roles of the
ligand binding domain of GM2AP in insulin secretion, HIT-T15 cells
were treated with anti-GM2AP antibodies in the presence of exog-
enous GM2AP. As shown in Fig. 3D, anti-GM2AP antibodies raised
against the b-cup structure signiﬁcantly inhibited GM2AP-induced
insulin secretion, whereas others targeting the amino-terminus
were without effect. These results suggested that GM2AP acceler-
ates insulin secretion through its ligand binding domain.4. Discussion
Adipose tissue synthesizes and secretes a large number of adi-
pokines that work as a network to regulate inﬂammation, insulin
action and glucose metabolism locally and systemically [20]. Most
recently, we have discovered a novel adipokine GM2AP from cul-
ture medium of 3T3-L1 adipocytes, and found increased expression
of GM2AP by adipogenesis [16]. In addition, treatment of cultured
adipocytes with GM2AP impaired insulin signaling [16]. In this
study, we showed that administration of GM2AP to mice signiﬁ-
cantly increased serum insulin levels. Treatment of HIT-T15 insuli-
noma cells with GM2AP induced calcium inﬂux resulted in a
stimulation of insulin secretion. Blockage of GM2AP function by
speciﬁc antibodies inhibited insulin secretion. As far as we know,
there have not been any earlier reports of adipokines with two ac-
tions; impairment of insulin signaling and stimulation of insulin
secretion.
Insulin secretion is subject to tight control by glucose, other
nutrients, neurotransmitters, and hormones. The mechanisms
underlying this multifactorial regulation can be schematized by a
hierarchical interaction between triggering and amplifying path-
ways [21]. When the concentration of glucose increases, b-cell
metabolism is activated, leading to closure of KATP channels in
the plasma membrane. The consequence is a depolarization of
the plasmamembrane, with opening of voltage-dependent calcium
channels and acceleration of calcium inﬂux that is a necessary and
sufﬁcient to trigger insulin secretion [18]. Stimulatory hormones
and neurotransmitters, such as glucagon-like peptide 1 and acetyl-
choline, also potentiate insulin secretion via their receptors
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Fig. 3. GM2AP stimulates insulin secretion in cultured cells. (A) HIT-T15 cells were loaded with Fluo-8, and then exposed to 1 lM carbachol (open circle) or 3 lg/ml of
GM2AP (solid circle) for 15 min. Fluorimetric data were acquired in a FDSS3000 scanning ﬂuorimeter. Results were representative of three wells. (B) HIT-T15 cells were
loaded with Fluo-8, and then incubated with various doses of GM2AP. Intracellular calcium concentrations relative to control were obtained from ﬂuorimetric data at 15 min.
(C) HIT-T15 cells were incubated with various doses of GM2AP for 20 min. Insulin contents in culture medium were determined by ELISA. (D) 2 lg/ml GM2AP was
preincubated with 10 lg/ml of anti-GM2AP antibodies prepared against amino-terminus (N) or b-cup structure (b-cup) within human GM2AP for 1 h at 37 C, and then added
to HIT-T15 cells. After 20 min, insulin contents in culture medium were determined by ELISA. Data shown are mean ± S.D. values. ⁄P < 0.05, N = 3.
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amino acids such as arginine depolarize b-cells because of their en-
try in a positively charged form, thus without direct interaction
with an ionic channel [19]. In this study, similar results with argi-
nine (Supplementary Fig. 2) suggest that GM2AP stimulates insulin
secretion without speciﬁc interaction with KATP channels or recep-
tors. In addition, our results as to the cooperative effects of GM2AP
with arginine or glucose on calcium inﬂux in HIT-T15 cells (Supple-
mentary Fig. 2) or serum insulin level in GTTs (Supplementary
Fig. 1B) might provide novel insights into how dietary nutrients
augment insulin secretion in obese subjects.
Our previous study has shown that GM2AP impairs insulin sig-
naling in cultured cells [16], however, administration of GM2AP to
mice hardly observed insulin resistance in spite of the increase in
serum insulin levels. Although incubation of cultured insulinoma
cells with 2 lg/ml of GM2AP for only 20 min stimulated insulin re-
lease (Fig. 3B), a 24 h-treatment of adipocytes with 10 lg/ml of
GM2AP was required to inhibit insulin signaling [16]. These results
suggest that interference in insulin signal transduction by GM2AP
in vivo requires chronic exposure to a higher concentration of
GM2AP. In contrast, the results from insulin transgenic mice
showed that a sustained elevated level of insulin leads to insulin
resistance [22]. Rizza et al. showed that continuous hyperinsuline-
mia in humans signiﬁcantly reduced glucose utilization [23].
Regardless of whether the insulin resistance or the basal hyperin-
sulinemia came ﬁrst, the hyperinsulinemia itself might perpetuate
the insulin resistance [22]. Further work is necessary to assess the
direct or indirect involvement of GM2AP in insulin resistance in
long-term experiments of normal or gene modiﬁed mice.
Enhanced serum c-GTP was evident on Day 15, however, a sig-
niﬁcant histological alteration in the liver was not observed (datanot shown). These results combined with the ﬁndings described
above might indicate that chronic elevated serum GM2AP levels
may cause hepatic or pancreatic dysfunction. In contrasts, the level
of serum leptin in mice was signiﬁcantly reduced by administra-
tion of GM2AP (Fig. 2C). In addition, GM2AP inhibited insulin-stim-
ulated leptin secretion in cultured adipocytes (Supplementary
Fig. 3). Leptin is a 16 kDa hormone secreted by adipocytes that
plays a key role in regulating food intake, body weight, and energy
homeostasis. Although the amount of body fat is the most impor-
tant determinant of circulating leptin levels, its production and
secretion are also modulated by numerous extrinsic factors [24].
A previous study suggested that increase of leptin secretion by
insulin is independent of the PI 3-kinase pathway in adipocytes
[24]. This PI 3-kinase independent signaling pathway involves
recruitment of a CAP/Cbl complex to the insulin receptor and sub-
sequent activation of a small Rho GTPase which is involved in insu-
lin-induced actin remodeling near the plasma membrane [25].
Thus, GM2AP may exhibit inhibitory effects on insulin-stimulated
leptin secretion mediated in a manner distinct from the distur-
bance of IR/PI 3-kinase pathway. A more complete understanding
of the molecular mechanisms by which GM2AP inhibits insulin-
induced leptin secretion would shed light on the role of GM2AP
in the development of obesity.
Gangliosides are known to exhibit regulatory roles in cell
growth, adhesion, cell–cell interactions and signal transduction
[26]. Many receptors tyrosine kinases including insulin receptor
are localized in lipid rafts. Previous studies indicated that accumu-
lation of ganglioside GM3 or ceramide in plasma membranes on
exposure to TNF-a dissociates IR from caveolin-1, which results
in interference with insulin signaling [27,28]. Inokuchi et al. have
advocated insulin resistance and type II diabetes as microdomain
K. Higashi et al. / FEBS Letters 585 (2011) 2587–2591 2591diseases [29]. In contrast, hyperinsulinemia is a risk factor for dia-
betes, and numerous studies have shown a relation of diabetes
with higher Alzheimer’s disease risk [30]. Our studies have shown
that GM2AP accelerates insulin secretion while impairing insulin
and NGF signal transductions through its ligand binding domain.
These ﬁndings provide novel insights into the mechanisms by
which GM2AP might be responsible for the development of obes-
ity-related disorders.
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